148 related articles for article (PubMed ID: 30227470)
1. Risk Evaluation and Mitigation Strategies With Elements to Assure Safe Use: Alignment of the Goals With the Tools to Manage Risk.
Cronin M; Berger S; Seligman PJ
Ther Innov Regul Sci; 2014 Nov; 48(6):724-733. PubMed ID: 30227470
[TBL] [Abstract][Full Text] [Related]
2. Risk Evaluation and Mitigation Strategies (REMSs): Are They Improving Drug Safety? A Critical Review of REMSs Requiring Elements to Assure Safe Use (ETASU).
Boudes PF
Drugs R D; 2017 Jun; 17(2):245-254. PubMed ID: 28160230
[TBL] [Abstract][Full Text] [Related]
3. Understanding risk evaluation and mitigation strategies in organ transplantation.
Gabardi S
Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
[TBL] [Abstract][Full Text] [Related]
4. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future Direction.
Wu J; Juhaeri J
Clin Ther; 2016 Dec; 38(12):2526-2532. PubMed ID: 27914632
[TBL] [Abstract][Full Text] [Related]
5. Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM.
Toyserkani GA; Huynh L; Morrato EH
Front Public Health; 2020; 8():43. PubMed ID: 32158741
[No Abstract] [Full Text] [Related]
6. Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use.
Sarpatwari A; Brown BL; McGraw SA; Dejene SZ; Abdurrob A; Santiago Ortiz AJ; Kesselheim AS
JAMA Netw Open; 2022 Jan; 5(1):e2144386. PubMed ID: 35050352
[TBL] [Abstract][Full Text] [Related]
7. Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018).
Huynh L; Toyserkani GA; Morrato EH
BMC Health Serv Res; 2021 Aug; 21(1):779. PubMed ID: 34362367
[TBL] [Abstract][Full Text] [Related]
8. Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use.
Sarpatwari A; Brown BL; McGraw SA; Dejene SZ; Abdurrob A; Kesselheim AS
PLoS One; 2023; 18(7):e0288008. PubMed ID: 37410756
[TBL] [Abstract][Full Text] [Related]
9. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
Shane R
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
[TBL] [Abstract][Full Text] [Related]
10. Risk evaluation and mitigation strategies: a focus on the mycophenolic acid preparations.
Rostas S; Kim M; Gabardi S
Prog Transplant; 2014 Mar; 24(1):33-6. PubMed ID: 24598563
[TBL] [Abstract][Full Text] [Related]
11. A guide to understanding and implementing risk evaluation and mitigation strategies in organ transplantation.
Gabardi S; Tichy EM
Prog Transplant; 2013 Mar; 23(1):58-62; quiz 63. PubMed ID: 23448822
[TBL] [Abstract][Full Text] [Related]
12. Mitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer?
Brooks MJ
Mayo Clin Proc; 2014 Dec; 89(12):1673-84. PubMed ID: 25441401
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
Rollman JE; Heyward J; Olson L; Lurie P; Sharfstein J; Alexander GC
JAMA; 2019 Feb; 321(7):676-685. PubMed ID: 30778596
[TBL] [Abstract][Full Text] [Related]
14. Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience.
Dharmani C; Wang E; Salas M; McCabe C; Diggs A; Choi Y; Jiang J; Keedy VL
Future Oncol; 2022 Apr; 18(13):1595-1607. PubMed ID: 35105158
[TBL] [Abstract][Full Text] [Related]
15. What is the quality of drug safety information for patients: An analysis of REMS educational materials.
Chan HW; Russell AM; Smith MY
Pharmacoepidemiol Drug Saf; 2018 Sep; 27(9):969-978. PubMed ID: 30003610
[TBL] [Abstract][Full Text] [Related]
16. Risk evaluation and mitigation strategies (REMS): educating the prescriber.
Nicholson SC; Peterson J; Yektashenas B
Drug Saf; 2012 Feb; 35(2):91-104. PubMed ID: 22171604
[TBL] [Abstract][Full Text] [Related]
17. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications.
Meyer BM
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S3-5. PubMed ID: 19966078
[TBL] [Abstract][Full Text] [Related]
18. A Descriptive Evaluation of Prescriber Perceptions and Experience With Risk Evaluation and Mitigation Strategy (REMS) Programs in an Integrated Health Care System.
Rashid N; Cheetham TC; Aranda G; Guerrero VN; Bartell H; Coghlan RJ
Ther Innov Regul Sci; 2015 Jul; 49(4):503-510. PubMed ID: 30222443
[TBL] [Abstract][Full Text] [Related]
19. APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.
American Pharmacists Association ; Bough M
J Am Pharm Assoc (2003); 2011; 51(3):340-58. PubMed ID: 21555285
[TBL] [Abstract][Full Text] [Related]
20. FDA's risk evaluation and mitigation strategies (REMS): effective and efficient safety tools or process poltergeist?
Wilson A; Milne CP
Food Drug Law J; 2011; 66(4):569-85, ii. PubMed ID: 24505829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
